SB

Sagimet Biosciences Inc.

SGMT·NASDAQ

$6.86

+1.3%
HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

At a Glance

Live Snapshot
Market Cap$223.51M
EPS-1.5800
P/E Ratio-4.34
Earnings Date08/12/2026

sgmt

Net Interest Income

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

SB

Sagimet Biosciences Inc. Competitors Analysis of Net Interest Income

SGMT · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
10.62M
-3.2%N/A27.0%
16.38M
-17.6%138.3%N/A
6.00M
20.2%81.8%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-8.66M
N/AN/AN/A
8.00M
-9.2%124.6%N/A
1.80M
-33.8%-2.3%0.6%
1.41M
39.0%198.0%N/A
10.10M
-15.3%N/AN/A
8.74M
-7.0%N/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
6.34M
42.6%206.4%N/A
SB

Sagimet Biosciences Inc. Fair Value Envelope

SGMT · NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.86, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

Intrinsic Value
Current Price: $6.86